Last updated: February 16, 2026
What Is the Current Market Status for NDC 00002-8799?
NDC 00002-8799 refers to a specific formulation of insulin (Humulin R U-500 KwikPen), a concentrated insulin used for managing diabetes in patients requiring higher doses. The drug's market presence is primarily within the US, where diabetes management is a significant medical and pharmaceutical focus.
The drug was approved by the FDA in 2016 and has gained market share due to its high-dose convenience and improved patient adherence. Its sales are driven by the increasing prevalence of diabetes, particularly in obesity-related cohorts. In 2022, Humulin R U-500 accounted for approximately 5% of the insulin market volume in the United States, with an estimated total sales volume exceeding 1.2 million prescriptions.
What Is the Competitive Landscape?
Humulin R U-500 is competing in a crowded insulin market with multiple distinguishes:
- Market Leaders: Novo Nordisk's Novolin and Eli Lilly's Humalog are dominant, with Novolin controlling roughly 60% of insulin prescriptions via traditional vials and pens.
- Innovation: The U-500 formulation has fewer direct substitutes but faces competition from newer concentrated insulins like Tresiba (insulin degludec) and Toujeo (insulin glargine U-300).
- Patient Segment: Targeted mainly at patients who require doses ≥200 units/day, representing around 10-15% of insulin users.
The product's unique selling point is reducing injection volume for high-dose patients, improving compliance and quality of life.
What Are the Revenue and Pricing Trends?
Pricing for NDC 00002-8799 varies by pharmacy and payer arrangements. The average wholesale price (AWP) in 2022 was approximately $275 per 5-pack pen. The average patient out-of-pocket cost ranged from $50 to $100, depending on insurance coverage.
Sales revenue projections indicate:
| Year |
Estimated Sales Volume |
Average Price |
Revenue Estimate |
| 2020 |
1.1 million prescriptions |
$260 |
$286 million |
| 2022 |
1.2 million prescriptions |
$275 |
$330 million |
| 2025 (Forecast) |
1.5 million prescriptions |
$280 |
$420 million |
These figures assume a compound annual growth rate (CAGR) of 6% driven by increasing diabetes prevalence and continued adoption of high-dose insulins.
What Are the Pricing Projections?
Price projections consider factors such as market competition, payer negotiations, and policy changes:
- Short-term (Next 2 Years): Slight increase in price (~2%) due to manufacturing cost inflation and premium positioning for high-dose convenience.
- Mid-term (3-5 Years): A possible stabilization or slight decline (~1-2%) driven by biosimilars and market pressures.
- Long-term: Adoption of biosimilars and new formulations could reduce price points by up to 10-15% in the next decade.
Given current trends, retail prices are unlikely to decrease significantly unless biosimilar competition enters the market, which remains unconfirmed as of 2023.
What Regulatory and Policy Factors Impact Market and Price?
- Biosimilar Approval: A biosimilar version of insulin U-500 has not yet been approved by the FDA as of 2023.
- Reimbursement Policies: Policies favoring biosimilar penetration and price transparency under the Inflation Reduction Act could exert downward pressure on prices.
- Medicare and Medicaid: Significant payers for high-dose insulins, with reimbursements aligned with CMS policies; potential price negotiations could influence future revenues.
What Are the Key Market Risks?
- Market Competition: Entry of biosimilars or branded alternatives with lower prices.
- Regulatory Changes: Price controls or reimbursement adjustments.
- Patent Expiry and Litigation: Patent protections expire within the next 5 years, opening pathways for generics or biosimilars.
Summary of Implications
- The market for NDC 00002-8799 is mature but has growth potential due to rising diabetes prevalence.
- Price stability is expected in the near term, with potential declines driven by biosimilars.
- Revenue growth is primarily driven by increased utilization rather than significant price hikes.
Key Takeaways
- The total US market volume for NDC 00002-8799 was approximately 1.2 million prescriptions in 2022.
- Average retail price per package was around $275, with revenue estimates approaching $330 million in 2022.
- Future sales growth hinges on diabetes prevalence and market penetration among high-dose patients.
- Market risks include biosimilar competition, policy shifts, and patent expirations.
FAQs
Q1: How does the price of NDC 00002-8799 compare to other insulin products?
It is priced higher than standard insulin vials (around $100 per vial) but comparable to other concentrated insulins such as Toujeo U-300 (approx. $330 per pen).
Q2: What factors influence the cost to patients?
Insurance coverage, pharmacy benefit management, and tier placement determine out-of-pocket costs, which range between $50 and $100 per prescription on average.
Q3: What is the outlook for biosimilar entry?
No biosimilar for insulin U-500 has been approved as of 2023. Regulatory pathways could open in the next 3-5 years, potentially impacting pricing and market share.
Q4: How does the market for high-dose insulin compare globally?
Most growth occurs in developed markets; global insulin markets are expanding at CAGR around 7%, but high-dose formulations like U-500 are primarily a North American focus due to dosing practices.
Q5: What incentives are in place for formulary adoption?
Payers favor drugs that improve patient adherence, reduce overall treatment costs, and have demonstrated clinical benefits. High-dose insulin like U-500 aligns with these goals for a specific patient cohort.
References
[1] IQVIA, "US Insulin Market Share Report," 2022.
[2] FDA, "Product Details for NDC 00002-8799," 2016.
[3] Medicare.gov, "Part B Reimbursement Policies," 2023.
[4] Pharma Intelligence, "Global Insulin Market Outlook," 2022.
